Latest News
Voyager signs cancer research mission management contract
6 October 2026 - Defence and space technology company Voyager Technologies (NYSE:VOYG) said on Tuesday that it has signed a contract with the Center for the Advancement of Science in Space to manage Symphony Biosciences' cancer research experime...
Orion Pharma to commercialise pembrolizumab biosimilar in Europe
6 October 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) announced on Tuesday an agreement with Qilu Pharma Europe to commercialise Qilu's intravenous (IV) pembrolizumab biosimilar in Europe.Under the agreemen...
Pillar Biosciences introduces oncoReveal Myeloid v2 Panel
6 October 2026 - US biotechnology company Pillar Biosciences on Monday announced the launch of the oncoReveal Myeloid v2 Panel, an expanded research-use-only (RUO) DNA next-generation sequencing (NGS) panel for myeloid malignancies.According to Pilla...
Zydus and MSN announce US launch of generic Adempas (Riociguat Tablets)
6 October 2026 - India-based pharmaceutical companies Zydus Lifesciences Limited and MSN Laboratories Private Limited announced on Monday the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States.Zydus and MSN say t...
AbbVie and Genmab report positive results from epcoritamab Phase 3 study in diffuse large B-cell lymphoma
6 October 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) and Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a ...